Kyle, Suzanne

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 5,198

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 487

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

Almeida, G. S., Bawn, C. M., Galler, M., Wilson, I., Thomas, H. D., Kyle, S., Curtin, N. J., Newell, D. R., & Maxwell, R. J. (2017) · NMR in Biomedicine

PARP inhibition in cancer therapyAdvanced NMR Techniques and Applications

Cited by 16